PURPOSE: We examined the association between caffeine and caffeinated beverage consumption in relation to the risk of exfoliation glaucoma or exfoliation glaucoma suspect (EG/EGS). METHODS: We followed 78,977 women from the Nurses' Health Study (NHS) and 41,202 men from the Health Professionals Follow-up Study (HPFS) who were at least 40 years of age, did not have glaucoma, and reported undergoing eye examinations from 1980 (NHS) or 1986 (HPFS) to 2008. Information on consumption of caffeine-containing beverages and potential confounders were repeatedly ascertained in validated follow-up questionnaires. Confirmation with medical record review revealed 360 incident EG/EGS cases. Multivariate rate ratios (RRs) for EG/EGS were calculated in each cohort and then pooled using meta-analytic techniques. RESULTS: Compared with participants whose cumulatively updated total caffeine consumption was <125 mg/day, participants who consumed ≥ 500 mg/day had a trend toward increased risk of EG/EGS that was not statistically significant (RR = 1.43; 95% confidence interval [CI], 0.98-2.08); P trend = 0.06). Compared to abstainers, those who drank ≥ 3 cups of caffeinated coffee daily were at increased risk of EG/EGS (RR = 1.66; 95% CI, 1.09-2.54; P trend = 0.02). These results were not materially altered after adjustment for total fluid intake. Associations were stronger among women with a family history of glaucoma (P interaction = 0.06 for coffee; P interaction = 0.03 for caffeine). We did not find associations with consumption of other caffeinated products (caffeinated soda, caffeinated tea, decaffeinated coffee or chocolate) and risk of EG/EGS (P trend ≥ 0.31). CONCLUSIONS: We observed a positive association between heavier coffee consumption with risk of EG/EGS in this large prospective study.
PURPOSE: We examined the association between caffeine and caffeinated beverage consumption in relation to the risk of exfoliation glaucoma or exfoliation glaucoma suspect (EG/EGS). METHODS: We followed 78,977 women from the Nurses' Health Study (NHS) and 41,202 men from the Health Professionals Follow-up Study (HPFS) who were at least 40 years of age, did not have glaucoma, and reported undergoing eye examinations from 1980 (NHS) or 1986 (HPFS) to 2008. Information on consumption of caffeine-containing beverages and potential confounders were repeatedly ascertained in validated follow-up questionnaires. Confirmation with medical record review revealed 360 incident EG/EGS cases. Multivariate rate ratios (RRs) for EG/EGS were calculated in each cohort and then pooled using meta-analytic techniques. RESULTS: Compared with participants whose cumulatively updated total caffeine consumption was <125 mg/day, participants who consumed ≥ 500 mg/day had a trend toward increased risk of EG/EGS that was not statistically significant (RR = 1.43; 95% confidence interval [CI], 0.98-2.08); P trend = 0.06). Compared to abstainers, those who drank ≥ 3 cups of caffeinated coffee daily were at increased risk of EG/EGS (RR = 1.66; 95% CI, 1.09-2.54; P trend = 0.02). These results were not materially altered after adjustment for total fluid intake. Associations were stronger among women with a family history of glaucoma (P interaction = 0.06 for coffee; P interaction = 0.03 for caffeine). We did not find associations with consumption of other caffeinated products (caffeinated soda, caffeinated tea, decaffeinated coffee or chocolate) and risk of EG/EGS (P trend ≥ 0.31). CONCLUSIONS: We observed a positive association between heavier coffee consumption with risk of EG/EGS in this large prospective study.
Authors: Martha Jaimes; David Rivera-Parra; Antonio Miranda-Duarte; Gerardo Valdés; Juan Carlos Zenteno Journal: Ophthalmic Genet Date: 2011-10-04 Impact factor: 1.803
Authors: S Salvini; D J Hunter; L Sampson; M J Stampfer; G A Colditz; B Rosner; W C Willett Journal: Int J Epidemiol Date: 1989-12 Impact factor: 7.196
Authors: John H Fingert; Alan L Robin; Todd E Scheetz; Young H Kwon; Jeffrey M Liebmann; Robert Ritch; Wallace L M Alward Journal: Trans Am Ophthalmol Soc Date: 2016-08
Authors: Michael A Hauser; Inas F Aboobakar; Yutao Liu; Shiroh Miura; Benjamin T Whigham; Pratap Challa; Joshua Wheeler; Andrew Williams; Cecelia Santiago-Turla; Xuejun Qin; Robyn M Rautenbach; Ari Ziskind; Michèle Ramsay; Steffen Uebe; Lingyun Song; Alexias Safi; Eranga N Vithana; Takanori Mizoguchi; Satoko Nakano; Toshiaki Kubota; Ken Hayashi; Shin-ichi Manabe; Shigeyasu Kazama; Yosai Mori; Kazunori Miyata; Nagahisa Yoshimura; Andre Reis; Gregory E Crawford; Francesca Pasutto; Trevor R Carmichael; Susan E I Williams; Mineo Ozaki; Tin Aung; Chiea-Chuen Khor; W Daniel Stamer; Allison E Ashley-Koch; R Rand Allingham Journal: Hum Mol Genet Date: 2015-08-25 Impact factor: 6.150
Authors: Jae H Kang; Trang VoPham; Francine Laden; Bernard A Rosner; Barbara Wirostko; Robert Ritch; Janey L Wiggs; Abrar Qureshi; Hongmei Nan; Louis R Pasquale Journal: J Glaucoma Date: 2020-06 Impact factor: 2.503